DPP-4 Diabetes Drugs May Cause Severe Joint Pain

The U.S. Food and Drug Administration (FDA) warned that Type 2 diabetes drugs in the Dipeptidyl peptidase-4 (DPP-4) inhibitors class may cause severe joint pain.

A new warning will be added to the labels of all drugs in the class, said the FDA. These medications control blood sugar by blocking an enzyme in the body called dipeptidyl peptidase-4, allowing the body to make more insulin. The first approved medication in this class is Merck’s Januvia (sitagliptin) which hit the market in 2006. From 2006 to 2013, the agency noted 33 cases of severe, disabling joint pain.

Visit Original Source